Bristol Myers Squibb Company (NYSE:BMY) Receives Average Recommendation of "Hold" from Analysts

Key Points

• Bristol Myers Squibb has received an average recommendation of "Hold" from 21 brokerages, with one sell rating, 15 hold ratings, four buy ratings, and one strong buy rating.
• The average twelve-month price objective set by analysts for Bristol Myers Squibb stock is $56.38.
• The company announced a quarterly dividend of $0.62 per share, resulting in an annualized dividend yield of 5.1%.

Bristol Myers Squibb Company (NYSE:BMY - Get Free Report) has earned a consensus recommendation of "Hold" from the twenty-one brokerages that are covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, fifteen have given a hold rating, four have issued a buy rating and one has issued a strong buy rating on the company. The average twelve-month price objective among analysts that have issued ratings on the stock in the last year is $56.3750.

Several research analysts recently issued reports on the company. Argus raised Bristol Myers Squibb to a "hold" rating in a research report on Friday, April 25th. Daiwa America lowered Bristol Myers Squibb from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, August 5th. Daiwa Capital Markets lowered Bristol Myers Squibb from an "outperform" rating to a "neutral" rating and set a $42.00 target price on the stock. in a research report on Tuesday, August 5th. William Blair reaffirmed a "market perform" rating on shares of Bristol Myers Squibb in a research report on Friday, April 25th. Finally, Jefferies Financial Group cut their price objective on Bristol Myers Squibb from $70.00 to $68.00 and set a "buy" rating on the stock in a report on Wednesday, April 23rd.

Bristol Myers Squibb Stock Performance

Shares of NYSE:BMY opened at $48.2470 on Thursday. The firm has a 50 day moving average of $47.14 and a 200 day moving average of $51.28. The company has a quick ratio of 1.11, a current ratio of 1.21 and a debt-to-equity ratio of 2.54. The company has a market capitalization of $98.20 billion, a price-to-earnings ratio of 19.45, a price-to-earnings-growth ratio of 2.47 and a beta of 0.36. Bristol Myers Squibb has a 52 week low of $42.96 and a 52 week high of $63.33.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last posted its earnings results on Thursday, July 31st. The biopharmaceutical company reported $1.46 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.07 by $0.39. The company had revenue of $12.27 billion for the quarter, compared to analyst estimates of $11.32 billion. Bristol Myers Squibb had a return on equity of 80.04% and a net margin of 10.58%.The firm's quarterly revenue was up .6% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $2.07 earnings per share. Bristol Myers Squibb has set its FY 2025 guidance at 6.350-6.650 EPS. On average, sell-side analysts predict that Bristol Myers Squibb will post 6.74 earnings per share for the current fiscal year.

Bristol Myers Squibb Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, August 1st. Stockholders of record on Thursday, July 3rd were issued a $0.62 dividend. The ex-dividend date of this dividend was Thursday, July 3rd. This represents a $2.48 dividend on an annualized basis and a dividend yield of 5.1%. Bristol Myers Squibb's dividend payout ratio is currently 100.00%.

Institutional Trading of Bristol Myers Squibb

Several hedge funds and other institutional investors have recently bought and sold shares of BMY. Coppell Advisory Solutions LLC purchased a new position in Bristol Myers Squibb during the second quarter worth approximately $1,899,000. Marex Group plc purchased a new position in Bristol Myers Squibb during the second quarter worth approximately $591,000. Asset Dedication LLC boosted its position in Bristol Myers Squibb by 6.7% during the second quarter. Asset Dedication LLC now owns 7,053 shares of the biopharmaceutical company's stock worth $326,000 after purchasing an additional 441 shares in the last quarter. Geneos Wealth Management Inc. boosted its position in Bristol Myers Squibb by 11.5% during the second quarter. Geneos Wealth Management Inc. now owns 92,231 shares of the biopharmaceutical company's stock worth $4,269,000 after purchasing an additional 9,477 shares in the last quarter. Finally, Kestra Investment Management LLC boosted its position in Bristol Myers Squibb by 43.7% during the second quarter. Kestra Investment Management LLC now owns 15,109 shares of the biopharmaceutical company's stock worth $699,000 after purchasing an additional 4,598 shares in the last quarter. 76.41% of the stock is owned by institutional investors and hedge funds.

About Bristol Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.